ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales. Therefore, the company is upgrading its earnings and cash flow outlook to
Preliminary Q3 results show organic revenue growth in local currencies to
ALK’s outlook update is as follows:
- Organic revenue growth is expected at around 8% equating to approximately
DKK 3.5 billion (previously towards the lower end of 8-12%). - Operating profit (EBITDA) is now expected to be
DKK 350-400 million (previously 300-350). - Free cash flow is now expected at approximately
DKK 0 million (previously negative ~200), reflecting the higher earnings and a positive change to working capital.
ALK will detail the revised full-year outlook in its nine-month interim report (Q3), which will be published Wednesday
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm,
Attachment
- FM_10_20UK_05112020
Source:
2020 GlobeNewswire, Inc., source